Efficacy, Safety, and Drug–Drug Interactions for Insomnia Therapy in COVID-19 Patients

References

• Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Heal. 2021;8. doi:10.3389/fpubh.2020.582932
   PubMed Web of Science ®Google Scholar
• Alonso-Lana S, Marquié M, Ruiz A, Boada M, Martínez-Pinilla E. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020;12:12. doi:10.3389/fnagi.2020.588872
   PubMed Web of Science ®Google Scholar
• Osterweil N. Coronasomnia: pervasive sleeplessness, self-medicating raise concerns of sleep experts. CHEST Physician; 2021. Accessed February 7, 2020. https://www.mdedge.com/chestphysician/article/234932/coronavirus-updates/coronasomnia-pervasive-sleeplessness-self?sso=true.
   Google Scholar
• Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Arch. 2012;463(1):121–137. doi:10.1007/s00424-011-1044-0
   PubMed Web of Science ®Google Scholar
• Tahara Y, Shibata S. Entrainment of the mouse circadian clock: effects of stress, exercise, and nutrition. Free Radic Biol Med. 2018;119:129–138. doi:10.1016/j.freeradbiomed.2017.12.026
   PubMed Web of Science ®Google Scholar
• Jahrami H, BaHammam AS, Bragazzi NL, Saif Z, Faris M, Vitiello MV. Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis. J Clin Sleep Med. 2021;17(2):299–313. doi:10.5664/jcsm.8930
   PubMed Web of Science ®Google Scholar
• Robillard R, Dion K, Pennestri M, et al. Profiles of sleep changes during the COVID‐19 pandemic: demographic, behavioural and psychological factors. J Sleep Res. 2021;30(1). doi:10.1111/jsr.13231
   PubMed Web of Science ®Google Scholar
• Uchimura N, Kamijo A, Kuwahara H, et al. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Med. 2012;13(10):1247–1253. doi:10.1016/j.sleep.2012.08.015
   PubMed Web of Science ®Google Scholar
• De Boer P, Drevets WC, Rofael H, et al. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol. 2018;32(6):668–677. doi:10.1177/0269881118773745
   PubMed Web of Science ®Google Scholar
• Brooks S, Jacobs GE, de Boer P, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol. 2019;33(2):202–209. doi:10.1177/0269881118822258
   PubMed Web of Science ®Google Scholar
• Connor KM, Mahoney E, Jackson S, et al. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol. 2016;19(8):pyw022. doi:10.1093/ijnp/pyw022
   PubMed Web of Science ®Google Scholar
• Kohsaka M, Kanemura T, Taniguchi M, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother. 2011;11(10):1389–1397. doi:10.1586/ern.11.128
   PubMed Web of Science ®Google Scholar
• Dahl T, Chen LB, Zammit G, Ahmad M, Roth T. Efficacy of SM‐1 in a transient insomnia model. Hum Psychopharmacol Clin Exp. 2019;34(6). doi:10.1002/hup.2713
   Web of Science ®Google Scholar
• Ferini Strambi L, Marelli S, Zucconi M, Galbiati A, Biggio G. Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study. J Neurol. 2017;264(7):1362–1369. doi:10.1007/s00415-017-8530-z
   PubMed Web of Science ®Google Scholar
• Herring WJ, Connor KM, Snyder E, et al. Suvorexant in Elderly Patients with Insomnia: pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Am J Geriatr Psychiatry. 2017;25(7):791–802. doi:10.1016/j.jagp.2017.03.004
   PubMed Web of Science ®Google Scholar
• Castro LS, Otuyama LJ, Fumo-dos-Santos C, Tufik S, Poyares D. Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial. Brazilian J Psychiatry. 2020;42(2):175–184. doi:10.1590/1516-4446-2019-0389
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Murphy P, Zammit G, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: a Phase 3 Randomized Clinical Trial. JAMA Netw open. 2019;2(12):e1918254. doi:10.1001/jamanetworkopen.2019.18254
   PubMed Web of Science ®Google Scholar
• Black J, Pillar G, Hedner J, et al. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. Sleep Med. 2017;36:86–94. doi:10.1016/j.sleep.2017.05.009
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, Patel H, Srinivas NR. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. Eur J Drug Metab Pharmacokinet. 2017;42(4):677–688. doi:10.1007/s13318-016-0385-7
   PubMed Web of Science ®Google Scholar
• Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010;38(8):1381–1391. doi:10.1124/dmd.110.034009
   PubMed Web of Science ®Google Scholar
• Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug‐drug interaction potential of lemborexant. Clin Pharmacol Drug Dev. 2021;10(6):681–690. doi:10.1002/cpdd.915
   PubMed Web of Science ®Google Scholar
• Garrouste C, Philipponnet C, Kaysi S, Enache I, Tiple A, Heng AE. Severe colchicine intoxication in a renal transplant recipient on cyclosporine. Transplant Proc. 2012;44(9):2851–2852. doi:10.1016/j.transproceed.2012.09.028
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036. doi:10.1001/jamacardio.2020.1834
   PubMed Web of Science ®Google Scholar
• Gandhi S, McArthur E, Mamdani MM, et al. Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies. Epilepsia. 2016;57(12):2067–2079. doi:10.1111/epi.13593
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Vol. 53. 5th. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596
   Google Scholar
• Buenaver LF, Townsend D, Ong JC. Delivering Cognitive Behavioral Therapy for Insomnia in the Real World. Sleep Med Clin. 2019;14(2):275–281. doi:10.1016/j.jsmc.2019.01.008
   PubMed Web of Science ®Google Scholar
• Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259–267. doi:10.5665/sleep.2386
   PubMed Web of Science ®Google Scholar
• Murphy P, Moline M, Mayleben D, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13(11):1289–1299. doi:10.5664/jcsm.6800
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Zammit G, Fietze I, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol. 2020;87(3):347–356. doi:10.1002/ana.25680
   PubMed Web of Science ®Google Scholar
• Zammit G, Dauvilliers Y, Pain S, Sebök Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94(21):e2222–e2232. doi:10.1212/WNL.0000000000009475
   PubMed Web of Science ®Google Scholar
• Roehrs TA, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 2012;26(8):1088–1095. doi:10.1177/0269881111424455
   PubMed Web of Science ®Google Scholar
• Sharma MK, Kainth S, Kumar S, et al. Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: a randomized, placebo-controlled trial. Clin Mol Hepatol. 2019;25(2):199–209. doi:10.3350/cmh.2018.0084
   PubMed Web of Science ®Google Scholar
• Horoszok L, Baleeiro T, D’Aniello F, et al. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum Psychopharmacol Clin Exp. 2014;29(3):266–273. doi:10.1002/hup.2395
   PubMed Web of Science ®Google Scholar
• Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7(2):129–140. doi:10.1016/S2213-2600(18)30294-7
   PubMed Web of Science ®Google Scholar
• Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res. 2012;64(4):597–606. doi:10.1002/acr.21595
   PubMed Web of Science ®Google Scholar
• Rosenberg RP, Hull SG, Lankford DA, et al. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014;10(10):1093–1100. doi:10.5664/jcsm.4108
   PubMed Web of Science ®Google Scholar
• Mohabbat AB, Mohabbat NML, Wight EC. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):764–766. doi:10.1016/j.mayocpiqo.2020.08.002
   PubMedGoogle Scholar
• Ramos E, López-Muñoz F, Gil-Martín E, et al. The Coronavirus Disease 2019 (COVID-19): key Emphasis on Melatonin Safety and Therapeutic Efficacy. Antioxidants. 2021;10(7):1152. doi:10.3390/antiox10071152
   Web of Science ®Google Scholar
• Scheer FAJL, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012;35(10):1395–1402. doi:10.5665/sleep.2122
   PubMed Web of Science ®Google Scholar
• Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433–1442. doi:10.5665/SLEEP.1294
   PubMed Web of Science ®Google Scholar
• Ivgy-May N, Ruwe F, Krystal A, Roth T. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Med. 2015;16(7):838–844. doi:10.1016/j.sleep.2015.04.001
   PubMed Web of Science ®Google Scholar
• Pinto L, Bittencourt L, Treptow E, Braga L, Tufik S. Eszopiclone versus zopiclone in the treatment of insomnia. Clinics. 2016;71(1):5–9. doi:10.6061/clinics/2016(01)02
   PubMed Web of Science ®Google Scholar